The safety of antiviral therapy and drug withdrawal for the prevention of mother-to-child transmission of HBV during pregnancy

被引:13
|
作者
Xiao, Li-Xin [1 ]
Chen, Yi-Ru [2 ]
Huang, Ping [3 ]
Mei, Yong-Yu [1 ]
Pan, Calvin Q. [4 ,5 ]
Lin, Chao-Shuang [1 ]
机构
[1] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[3] Peoples Hosp Lianjiang, Dept Infect Dis, Lianjiang, Guangdong, Peoples R China
[4] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Dept Med, Beijing, Peoples R China
[5] NYU, Dept Med, Div Gastroenterol & Hepatol, Langone Hlth,Sch Med, 132-21 41 Ave, New York, NY 11355 USA
关键词
antiviral therapy; drug withdrawal; hepatitis B virus; mother-to-child transmission; HEPATITIS-B-VIRUS; REDUCES PERINATAL TRANSMISSION; TENOFOVIR DISOPROXIL FUMARATE; SURFACE-ANTIGEN; INFECTION; EFFICACY; TELBIVUDINE; FLARES; WOMEN; PREDICTORS;
D O I
10.1002/jmv.26011
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacy of prenatal antiviral therapy (AVT) for preventing the vertical transmission of hepatitis B virus (HBV) is well demonstrated. However, data are limited regarding the safety of postpartum cessation of AVT, which may induce alanine aminotransferase (ALT) elevation. We aimed to investigate the necessity of prolonging maternal AVT after delivery. Chronic hepatitis B mothers at the immune-tolerant phase with HBV DNA levels >6 log(10) IU/mL were prospectively enrolled and received AVT during the third trimester until delivery. Patients were offered to discontinue AVT either at delivery or postpartum week (PPW) 6. In addition, mothers who deferred AVT during pregnancy served as the control group. All mothers were followed until PPW 52 for clinical and virological parameters of hepatitis flares. Among 118 mothers recruited, 91 received AVT with 53 (group A) and 24 (group B) discontinue their treatment at delivery and PPW 6, respectively. Twenty-seven mothers who deferred AVT during pregnancy were followed as the control (group C). A total of 104 of 118 mothers who completed the study, 50% (52/104) had postpartum-elevated ALT levels, which were mild and moderate except 6 of 104 (5.77%) of patients had levels >= 5 times the upper limit of normal; 70% (36/52) of the ALT flares occurred within 12 weeks after delivery. In subgroup analyses, the frequency of ALT elevation was similar among the groups A vs B vs C (50.9% [27/53] vs 58.3% [14/24] vs 40.7% [11/27], respectively;P = .447), as well as the mean peak ALT level (108.4/74.1/126.7 U/L in groups A/B/C, respectively;P = .291). Although postpartum ALT flares were common for mothers with or without AVT during pregnancy, most cases of ALT elevation were mild to moderate. Our study observed that extending AVT to PPW 6 did not affect maternal outcomes and ATV should be discontinued at birth. Close monitoring is warranted as severe flares rarely occurred.
引用
收藏
页码:3381 / 3389
页数:9
相关论文
共 50 条
  • [21] Impact of antiviral therapy for blocking mother-to-child transmission on virus quasispecies in pregnant women with chronic HBV infection
    Liu, Zhihua
    Guo, Huijie
    Gao, Yunfei
    Yin, Xueru
    Hu, Jing
    JOURNAL OF HEPATOLOGY, 2020, 73 : S851 - S851
  • [22] Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery
    Zeng, Q. -L.
    Xu, G. -H.
    Wang, B.
    Li, Z. -Q.
    Yu, Z. -J.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S502 - S503
  • [23] Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery
    Zeng, Q-L
    Xu, G-H
    Wang, B.
    Li, Z-Q
    Yu, Z-J
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (05) : 612 - 613
  • [24] Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission
    Townsend, Claire L.
    Tookey, Pat A.
    Newell, Marie-Louise
    Cortina-Borja, Mario
    ANTIVIRAL THERAPY, 2010, 15 (05) : 775 - 783
  • [25] Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe
    Bailey, Heather
    Townsend, Claire
    Cortina-Borja, Mario
    Thorne, Claire
    ANTIVIRAL THERAPY, 2011, 16 (06) : 895 - 903
  • [26] Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus
    Eke, Ahizechukwu C.
    Eleje, George U.
    Eke, Uzoamaka A.
    Xia, Yun
    Liu, Jiao
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (02):
  • [27] Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission
    Chamroonkul, Naichaya
    Piratvisuth, Teerha
    PEDIATRIC DRUGS, 2017, 19 (03) : 173 - 181
  • [28] Dual Therapy With Lamivudine plus Protease Inhibitor During Pregnancy for Prevention of Mother-to-Child Transmission of HIV-1
    Gliga, Smaranda S.
    Clavel, Cyril O.
    Alix, Anne F.
    Dommergues, Marc A.
    Quetin, Frederique
    Marcelin, Anne G.
    Schneider, Luminita
    Stitou, Hind
    Calin, Ruxandra
    Caby, Fabienne
    Valantin, Marc A.
    Katlama, Christine
    Tubiana, Roland
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (05) : E159 - E163
  • [29] Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission
    Naichaya Chamroonkul
    Teerha Piratvisuth
    Pediatric Drugs, 2017, 19 : 173 - 181
  • [30] The Efficacy And Safety Of Telbivudine And/Or Tenofovir Disoproxil In Pregnancy For Prevention Of Mother-To-Child Transmission Of Hepatitis B Virus
    Zhang, Yanqiong
    Huang, Hongfei
    Wu, Quanxin
    Wang, Yuming
    HEPATOLOGY, 2015, 62 : 1195A - 1195A